Overview
The development of novel antibacterial therapies is lagging behind the rise of resistance to antibiotics and threatens to become a critical public health emergency.
To help address the unmet need for new antibiotic therapies, CTTI conducted research and issued findings on patient and physician perspectives and considerations as it relates to using antibacterial drugs developed through streamlined development processes.
Solutions
Search AllRecommendation Summary
Recommendations
Resources
Related Items
- Patient and physician attitudes regarding risk and benefit in streamlined development programmes for antibacterial drugs: a qualitative analysis
- Streamlining Antibacterial Drug Development Programs To Address Unmet Medical Need: Patient And Provider Attitudes On A Modified Benefit-Risk Calculus
- The Use of Antibacterial Drugs Developed via Streamlined Approaches for Serious Infections Where There is Unmet Need: Understanding Patient and Physician Perspectives and Considerations to Take Forward
- Respiratory Tract Infection Clinical Trials, 2007-2012: A Systematic Review of ClinicalTrials.gov
- Statistical Issues Think Tank II
- Anti-Bacterial Drug Development: Issues in the Design of Trials in Patients with Unmet Need and in Patients with Hospital-Acquired and Ventilator Associated Bacterial Pneumonia
- CTTI Antibacterial Drug Development: Statistical Issues Think Tank Meeting
- CTTI Statistics Think Tank for Anti-Bacterial Drug Development by Lisa LaVange
News
- CTTI Publishes Findings on Patient & Physician Perceptions of Streamlined Development for Antibacterial DrugsOver 2 million people in the United States are estimated to become infected with drug-resistant bacteria each year, so new antibacterial therapies are desperately needed. Streamlined drug development approaches have ...